Supernus Pharmaceuticals, Inc.
SUPN
$32.22
$0.872.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 174.16M | 175.69M | 168.33M | 143.64M | 164.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.16M | 175.69M | 168.33M | 143.64M | 164.31M |
| Cost of Revenue | 26.10M | 17.58M | 17.92M | 16.31M | 19.63M |
| Gross Profit | 148.06M | 158.11M | 150.41M | 127.34M | 144.69M |
| SG&A Expenses | 81.61M | 81.25M | 85.90M | 86.52M | 81.28M |
| Depreciation & Amortization | 18.24M | 19.49M | 20.11M | 20.14M | 21.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 154.60M | 147.36M | 150.11M | 147.89M | 145.33M |
| Operating Income | 19.56M | 28.33M | 18.21M | -4.25M | 18.99M |
| Income Before Tax | 26.38M | 44.94M | 26.30M | 243.00K | 990.00K |
| Income Tax Expenses | 11.05M | 6.45M | 6.39M | 119.00K | -185.00K |
| Earnings from Continuing Operations | 15.33M | 38.50M | 19.92M | 124.00K | 1.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.33M | 38.50M | 19.92M | 124.00K | 1.18M |
| EBIT | 19.56M | 28.33M | 18.21M | -4.25M | 18.99M |
| EBITDA | 38.41M | 48.43M | 38.93M | 16.50M | 40.67M |
| EPS Basic | 0.28 | 0.70 | 0.36 | 0.00 | 0.02 |
| Normalized Basic EPS | 0.28 | 0.37 | 0.25 | -0.01 | 0.24 |
| EPS Diluted | 0.27 | 0.69 | 0.36 | 0.00 | 0.02 |
| Normalized Diluted EPS | 0.27 | 0.36 | 0.25 | -0.01 | 0.24 |
| Average Basic Shares Outstanding | 55.47M | 55.15M | 54.98M | 54.80M | 54.65M |
| Average Diluted Shares Outstanding | 56.46M | 56.02M | 55.72M | 55.63M | 55.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |